VaxCyte

VaxCyte

Edit info

  • Founded: 2013
  • Location: San Carlos, CA
  • Employee range: 50 - 200
  • Clinical stage: Clin2
  • Therapy area: Pneumococcal disease
  • Drug types: INF, VAC, PED, GER
  • Lead product: VAX-24
  • Funding: $575M stock Apr 2023; $690M stock Oct 2022; $100M stock Jan 2022; $287.5M IPO Jun 2020; $110M D Mar 2020; $85M C Jun 2018; $64M B Mar 2017; $22M A Jul 2015


vaxcyte.com

linkedin.com

job board


Business:

Conjugate vaccines and protein-based vaccines

Drug notes:

Also Clin2 65+ pneumococcal disease, Clin2 infant pneumococcal disease; VAX-XP Clin0 pneumococcal disease; VAX-A1 Clin0 strep infections; VAX-PG Clin0 periodontitis; VAX-GI Clin0 shigella

About:

Vaxcyte is creating therapeutic vaccines to eliminate bacterial infections. Bacterial infections remain one of the greatest public health challenges, including infections caused by pneumococcal disease and periodontitis. Many emerging serotypes of pneumococcal disease are not covered by current vaccines. Vaxcyte aims to fix this problem by using their chemistry and cell-free protein synthesis platform (XpressCF) to engineer more effective vaccines. The valency of the vaccines is enhanced to offer precise, site-specific conjugation to immune epitopes. Vaxcyte’s lead candidate, VAX-24, is in Phase 2 clinical trials to be later used for pneumococcal disease with 3 other candidates in earlier stage development.

Post a job


© 2025 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com